Findings among patients with type 2 diabetes and history of cardiovascular disease or current kidney disease<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, June 29, 2021 (HealthDay News) — For patients with type 2 diabetes and a history of cardiovascular disease or current kidney disease, the risk for adverse cardiovascular events is lower with efpeglenatide, an exendin-based glucagon-like peptide 1 receptor agonist, than placebo, according to a study published online June 28 in the New England Journal of Medicine<\/em> to coincide with the annual meeting of the American Diabetes Association, held virtually from June 25 to 29.<\/p>\n Hertzel C. Gerstein, M.D., from Hamilton Health Sciences in Canada, and colleagues conducted a trial of efpeglenatide among participants with type 2 diabetes and a history of cardiovascular disease or current kidney disease plus one or more cardiovascular risk factors. Participants were randomly assigned to receive weekly subcutaneous injections of efpeglenatide (2,717 participants) at a dose of 4 or 6 mg or placebo (1,359 participants).<\/p>\n The researchers found that an incident major adverse cardiovascular event occurred in 7.0 and 9.2 percent of those assigned to receive efpeglenatide and placebo, respectively, during a median follow-up of 1.81 years (3.9 and 5.3 events per 100 person-years, respectively; hazard ratio, 0.73; 95 percent confidence interval, 0.58 to 0.92; P < 0.001 for noninferiority; P = 0.007 for superiority). A composite renal outcome event occurred in 13.0 and 18.4 percent of those randomly assigned to receive efpeglenatide and placebo, respectively (hazard ratio, 0.68; 95 percent confidence interval, 0.57 to 0.79; P < 0.001).<\/p>\n “We are encouraged that this once-a-week injection safely and effectively reduced cardiovascular and progression of kidney disease in patients with long-standing diabetes who had a high prevalence of cardiovascular and kidney disease,” Gerstein said in a statement.<\/p>\n The study was funded by Sanofi, which manufactures efpeglenatide.<\/p>\n Abstract\/Full Text<\/a><\/p>\n